BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 25, 2011
View Archived Issues
Serum KL-6 level is a biomarker of prognosis in diffuse alveolar hemorrhage syndrome
Read More
Genmab provides pipeline and technology update
Read More
Interim phase II data disclosed on nimotuzumab plus irinotecan in gastric cancer
Read More
StronBone Sr-substituted bioactive glass implants show promise in bone grafting
Read More
Phase I data reported on recombinant angiotensin-converting enzyme 2
Read More
Flex-590 confers chondroprotection in a model of osteoarthritis
Read More
AMG-369 reduces severity of experimental autoimmune encephalomyelitis
Read More
AstraZeneca responds to FDA complete response letter for Brilinta
Read More
CHMP issues positive opinion on Eisai's Halaven for metastatic breast cancer
Read More
Cytori Therapeutics' ADVANCE trial of ADRCs is cleared to begin in the Netherlands
Read More
New blockers of cyclic nucleotide-regulated HCN1 channel claimed
Read More
PGxHealth presents new adenosine A2A receptor agonists
Read More
Novartis receives Swiss and Austrian approval for Gilenya in relapsing-remitting MS
Read More
CHMP recommends European marketing authorization for Trobalt
Read More
R-Tech Ueno completes phase IIa RK-023 trial in androgenetic alopecia
Read More
CHMP recommends new indications of INOmax
Read More
New melanin-concentrating hormone MCH1 receptor antagonists claimed
Read More
FDA grants priority review for Optimer Pharma's fidaxomicin NDA
Read More
Enrollment complete in pivotal phase III trial of delayed-release cysteamine
Read More
Novel PI3K inhibitors described at Novartis
Read More
FDA approves Viibryd for major depressive disorder
Read More
Otuska submits application to extend indication for Abilify in Japan
Read More
FDA recommends approval of Bayer's gadobutrol injection
Read More
Eisai decides against submitting marketing applications for eritoran for severe sepsis
Read More
Eisai set to submit U.S. and E.U. marketing authorization applications for perampanel
Read More